2013-10-07 11:51:23 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Starlake Bioscience Co Inc Zhqng Gngdng (600866) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Starlake Bioscience Co Inc Zhqng Gngdng (600866). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Starlake Bioscience Co Inc Zhqng Gngdng investor.
Report Summary: Starlake Bioscience Co Inc Zhqng Gngdng is a low quality company with a neutral outlook. Starlake Bioscience Co Inc Zhqng Gngdng has weak business growth and is run by inefficient management. The trend in Starlake Bioscience Co Inc Zhqng Gngdng fair value exchange rate against its closest rated-competitor, Chenguang Biotech Group Co Ltd, has been appreciating over the past 2 weeks. When compared to its closest competitor, Starlake Bioscience Co Inc Zhqng Gngdng
shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Starlake Bioscience Co Inc Zhqng Gngdng for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.